- Home
- BOLT vs GTBP Comparison
BOLT vs GTBP Comparison
Compare BOLT & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BOLT | GTBP |
|---|---|---|
| Founded | 2015 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 8.8M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BOLT | GTBP |
|---|---|---|
| Price | $3.99 | $0.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $34.00 | N/A |
| AVG Volume (30 Days) | 29.4K | ★ 1.4M |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,695,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $133.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.07 | N/A |
| 52 Week Low | $3.75 | $0.26 |
| 52 Week High | $7.20 | $3.09 |
Technical Indicators
Market Signals| Indicator | BOLT | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 39.33 | 56.83 |
| Support Level | N/A | $0.39 |
| Resistance Level | $5.05 | $0.57 |
| Average True Range (ATR) | 0.39 | 0.05 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 17.50 | 59.47 |
Price Performance
Historical ComparisonAbout BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.